Profil
Mark Toomey is President at Canton Strategic Holdings, Inc. since 2025.
Former roles include Head-North America Asset Management Sales at Galaxy Digital Holdings, Inc. from 2021 to 2025, and Managing Director-Equity Institutional Derivatives at The Goldman Sachs Group, Inc. Education includes an undergraduate degree from Syracuse University and an MBA from Georgetown University.
Aktive Positionen von Mark Toomey
| Unternehmen | Position | Beginn |
|---|---|---|
| CANTON STRATEGIC HOLDINGS, INC. | Präsident | 06.11.2025 |
Ehemalige bekannte Positionen von Mark Toomey
| Unternehmen | Position | Ende |
|---|---|---|
Galaxy Digital Holdings Ltd.
Galaxy Digital Holdings Ltd. Investment Banks/BrokersFinance Engages in crypto trading, lending, advisory and mining, custody platform & block chain infrastructure development and asset management business | Vertrieb & Marketing | 01.02.2025 |
| THE GOLDMAN SACHS GROUP, INC. | Corporate Officer/Principal | - |
Ausbildung von Mark Toomey
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
The Goldman Sachs Group, Inc.
The Goldman Sachs Group, Inc. Investment Banks/BrokersFinance Provides investment banking, asset, wealth management and platform services | Finance |
Syracuse University
Syracuse University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Georgetown University
Georgetown University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Galaxy Digital Holdings Ltd.
Galaxy Digital Holdings Ltd. Investment Banks/BrokersFinance Engages in crypto trading, lending, advisory and mining, custody platform & block chain infrastructure development and asset management business | Finance |
Tharimmune, Inc.
Tharimmune, Inc. BiotechnologyHealth Technology Operates as a pre-clinical biotechnology company that develops novel therapeutic candidates targeting ferroptosis | Health Technology |
















